CACNA1G-AS1: A Potential Drug Target and Biomarker (G253962)

Target Name: CACNA1G-AS1

NCBI ID: G253962

CACNA1G-AS1

Other Name(s): CAS1 | CACNA1G antisense RNA 1

CACNA1G-AS1: A Potential Drug Target and Biomarker

CACNA1G-AS1, also known as CAS1, is a protein that is expressed in the central nervous system (CNS) and is involved in the function of dopamine (D2) receptors. The discovery of CACNA1G-AS1 as a potential drug target and biomarker has significant implications for the treatment of various neurological disorders.

CACNA1G-AS1 Relevance in Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder that is characterized by symptoms such as tremors, rigidity, and difficulty with movement. The exact cause of Parkinson's disease is not known, but it is thought to involve the loss of dopamine-producing neurons in the brain. CACNA1G-AS1 has been shown to play a role in the regulation of dopamine release and may be a potential drug target for the treatment of Parkinson's disease.

CACNA1G-AS1 Interacts with dd-RAS2

In Parkinson's disease, dopamine-producing neurons are thought to be affected by a build-up of dopamine in the brain, which can cause the symptoms associated with the disease. CACNA1G-AS1 has been shown to interact with dd-RAS2, a protein that is involved in the regulation of dopamine release. This interaction suggests that CACNA1G-AS1 may be a useful target for the treatment of Parkinson's disease.

CACNA1G-AS1 as a Biomarker

One of the challenges in the treatment of Parkinson's disease is the lack of definitive diagnostic criteria, which makes it difficult to determine the effectiveness of potential treatments. CACNA1G-AS1 has been shown to be expressed in the brain and may be a potential biomarker for the disease. Further research is needed to determine the utility of CACNA1G-AS1 as a biomarker for the diagnosis and treatment of Parkinson's disease.

CACNA1G-AS1 as a Potential Drug Target

The identification of CACNA1G-AS1 as a potential drug target has significant implications for the treatment of various neurological disorders, including Parkinson's disease. The interaction between CACNA1G-AS1 and dd-RAS2 suggests that CACNA1G-AS1 may be a useful target for the treatment of Parkinson's disease and other neurological disorders. Further research is needed to determine the effectiveness of CACNA1G-AS1 as a drug.

Protein Name: CACNA1G Antisense RNA 1

The "CACNA1G-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CACNA1G-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets